ARAV

Aravive, Inc. [ARAV] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ARAV Stock Summary

In the News

01:31 29 Mar 2024 ARAV

Aravive (ARAV) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aravive (ARAV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

07:32 29 Mar 2024 ARAV

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

Aravive (ARAV) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.61 per share a year ago.

08:34 29 Mar 2024 ARAV

Why Is Aravive (ARAV) Stock Down 58% Today?

Aravive (NASDAQ: ARAV ) stock is plummeting on Thursday following the release of results from a Phase 3 clinical trial. The bad news hitting ARAV stock today is that its Phase 3 AXLerate-OC trial did not meet its primary endpoint.

07:05 29 Mar 2024 ARAV

Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held October 20-24, 2023 in Madrid, Spain. Posters will feature clinical data from the Company's ongoing Phase 1b/2 trials of batiraxcept in clear cell renal cell carcinoma (ccRCC) and pancreatic adenocarcinoma (PDAC).

09:46 29 Mar 2024 ARAV

3 Short-Squeeze Stocks Set for a Spectacular Gamma Squeeze Rally

At the heart of every idea for short-squeeze stocks to buy is the ability to make a massive amount of money in a short time period. For a quick recap, those attempting to spark a gamma squeeze essentially take the opposite side of the bearish bet.

04:05 29 Mar 2024 ARAV

Aravive To Participate in the Jefferies Global Healthcare Conference

HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Jefferies Global Healthcare Conference being held on June 7-9, 2023 in New York, NY.

05:00 29 Mar 2024 ARAV

Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023

HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. The poster presentation will highlight updated results from the Phase 2 portion of the trial in patients with advanced or metastatic ccRCC with or without prior line(s) of therapy, including immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies. In addition, an abstract highlighting batiraxcept data in pancreatic adenocarcinoma (PDAC) will be published in the 2023 ASCO Annual Meeting Proceedings.

04:37 29 Mar 2024 ARAV

7 Short-Interest Stocks to Target for Explosive Gains

Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks.

01:43 29 Mar 2024 ARAV

What Makes Aravive (ARAV) a New Buy Stock

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

02:14 29 Mar 2024 ARAV

7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy

Although the concept of gambling on short-squeeze stocks present risks, certain market ideas drive hedge funds crazy. By this statement, I'm referring to companies that speculators believe in their hearts should tumble for various reasons.

ARAV Financial details

Company Rating
Strong Buy
Market Cap
2.95M
Income
-81.15M
Revenue
7M
Book val./share
0.02
Cash/share
0.11
Dividend
-
Dividend %
-
Employees
23
Optionable
No
Shortable
Yes
Earnings
13 Mar 2024
P/E
-0.11
Forward P/E
-0.16
PEG
0.03
P/S
1.25
P/B
5.3
P/C
0.36
P/FCF
-0.15
Quick Ratio
0.87
Current Ratio
0.98
Debt / Equity
1.43
LT Debt / Equity
0.18
-
-
EPS (TTM)
-1.17
EPS next Y
-0.25
EPS next Q
1.58
EPS this Y
16.84%
EPS next Y
-78.35%
EPS next 5Y
-78.35%
EPS last 5Y
-26.91%
Revenue last 5Y
46.13%
Revenue Q/Q
116.33%
EPS Q/Q
16.67%
-
-
-
-
SMA20
-66.67%
SMA50
-71.43%
SMA100
-
Inst Own
6.66%
Inst Trans
0.3%
ROA
-622%
ROE
705%
ROC
-7.97%
Gross Margin
100%
Oper. Margin
-373%
Profit Margin
-1160%
Payout
-
Shs Outstand
73.56M
Shs Float
45.08M
-
-
-
-
Target Price
0.25
52W Range
0.04-2.46
52W High
-
52W Low
-
RSI
20.6
Rel Volume
-
Avg Volume
2.24M
Volume
Perf Week
0.25%
Perf Month
-68.5%
Perf Quarter
-
Perf Half Y
-70.9%
-
-
-
-
Beta
2.186
-
-
Volatility
0%, 0.04%
Prev Close
0%
Price
0.0401
Change
0%

ARAV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.190.410.360.370.25
Net income per share
-10.64-1.75-2.17-1.9-2.22
Operating cash flow per share
-4.08-1.47-0.77-1.6-1.79
Free cash flow per share
-4.37-1.47-0.77-1.6-1.79
Cash per share
7.955.623.832.961.48
Book value per share
8.365.963.042.10.29
Tangible book value per share
8.315.943.042.10.29
Share holders equity per share
8.365.963.042.10.29
Interest debt per share
1.151.090.670.430.3
Market cap
25.24M158.42M89.06M43.95M48.01M
Enterprise value
-24.43M103.52M37.03M-9.1M594.04K
P/E ratio
-0.33-7.82-2.6-1.15-0.59
Price to sales ratio
18.4133.3315.675.915.25
POCF ratio
-0.86-9.27-7.32-1.37-0.74
PFCF ratio
-0.8-9.27-7.32-1.37-0.74
P/B Ratio
0.422.291.851.044.51
PTB ratio
0.422.291.851.044.51
EV to sales
-17.8221.786.51-1.220.07
Enterprise value over EBITDA
0.69-5.68-1.930.22-0.01
EV to operating cash flow
0.83-6.06-3.040.28-0.01
EV to free cash flow
0.78-6.06-3.040.28-0.01
Earnings yield
-3.02-0.13-0.38-0.87-1.69
Free cash flow yield
-1.24-0.11-0.14-0.73-1.36
Debt to equity
0.10.180.220.210.59
Debt to assets
0.080.150.160.130.1
Net debt to EBITDA
1.43.012.711.310.67
Current ratio
29.4226.255.653.222.73
Interest coverage
-31.05000-15.4
Income quality
0.380.940.40.820.85
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
19.982.882.31.421.43
Research and developement to revenue
8.082.73.15.047.33
Intangibles to total assets
00000
Capex to operating cash flow
0.070000
Capex to revenue
-1.540000
Capex to depreciation
-1.99000-0.01
Stock based compensation to revenue
11.770.720.350.30.28
Graham number
44.7415.3112.199.483.83
ROIC
-1.05-0.26-0.51-0.69-3.58
Return on tangible assets
-1.1-0.25-0.51-0.56-1.3
Graham Net
6.644.652.671.670.04
Working capital
55.06M64.98M51.83M42.66M35.6M
Tangible asset value
59.6M68.83M47.96M42.22M10.66M
Net current asset value
47.47M54.49M43.32M36.29M4.64M
Invested capital
0.10.180.220.210.59
Average receivables
303K1.56M1.38M147.5K59K
Average payables
3.77M2.26M3.7M3.74M5.71M
Average inventory
-311K-373.5K1.01M614.5K-1.42M
Days sales outstanding
161.33192.2916.821.623.4
Days payables outstanding
073.1999.9125.8347.79
Days of inventory on hand
0-3.5544.58-8.97-10.47
Receivables turnover
2.261.921.7225.52107.49
Payables turnover
04.993.6514.137.64
Inventory turnover
0-102.698.19-40.67-34.85
ROE
-1.27-0.29-0.71-0.9-7.59
Capex per share
-0.290000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.160.020.020.010.04
Net income per share
-0.48-0.61-1.080.180.28
Operating cash flow per share
-0.62-0.23-0.23-0.18-0.13
Free cash flow per share
-0.62-0.23-0.23-0.18-0.13
Cash per share
0.910.850.470.180.11
Book value per share
0.490.17-0.51-0.20.02
Tangible book value per share
0.490.17-0.51-0.20.02
Share holders equity per share
0.490.17-0.51-0.20.02
Interest debt per share
0.160.10.490.030.03
Market cap
24.93M83.08M151.43M125.54M10.04M
Enterprise value
1.68M35.66M119.02M110.15M3.94M
P/E ratio
-0.43-0.54-0.461.740.12
Price to sales ratio
5.0356.36101.5698.543.64
POCF ratio
-1.32-5.84-8.53-7.11-1.02
PFCF ratio
-1.32-5.83-8.53-7.11-1.02
P/B Ratio
1.667.8-3.92-6.345.9
PTB ratio
1.667.8-3.92-6.345.9
EV to sales
0.3424.1979.8386.461.43
Enterprise value over EBITDA
-0.1-1.87.67-2.63-0.1
EV to operating cash flow
-0.09-2.5-6.7-6.24-0.4
EV to free cash flow
-0.09-2.5-6.7-6.24-0.4
Earnings yield
-0.59-0.46-0.540.142.11
Free cash flow yield
-0.76-0.17-0.12-0.14-0.98
Debt to equity
0.310.59-0.09-0.151.43
Debt to assets
0.110.10.080.120.19
Net debt to EBITDA
1.422.39-2.090.370.16
Current ratio
1.592.731.931.550.98
Interest coverage
-112.5790.290.4600
Income quality
1.210.490.36-0.98-0.46
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.572.32.342.411.07
Research and developement to revenue
3.7712.1810.678.473.17
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
0-0.01000
Capex to depreciation
0-0.05000
Stock based compensation to revenue
0.130.390.460.60.11
Graham number
2.311.523.530.90.37
ROIC
-0.64-1.25-0.82.41-3.25
Return on tangible assets
-0.35-0.62-1.910.71.63
Graham Net
0.170.02-0.6-0.27-0.04
Working capital
14.11M35.6M18.87M7.82M-215K
Tangible asset value
15.04M10.66M-38.61M-19.82M1.7M
Net current asset value
10.66M4.64M-42.59M-23.51M-1.79M
Invested capital
0.310.59-0.09-0.151.43
Average receivables
3M3.04M42.5K00
Average payables
6.76M8.79M9.28M6.84M4.66M
Average inventory
0.5-960.5K-960.5K00
Days sales outstanding
108.965.19000
Days payables outstanding
42.5343.9455.3932.4755.91
Days of inventory on hand
0-9.63000
Receivables turnover
0.8317.34000
Payables turnover
2.122.051.622.771.61
Inventory turnover
18.67M-9.35000
ROE
-0.97-3.62.12-0.9112.48
Capex per share
00000

ARAV Frequently Asked Questions

What is Aravive, Inc. stock symbol ?

Aravive, Inc. is a US stock , located in Houston of Tx and trading under the symbol ARAV

Is Aravive, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $0.25. The lowest prediction is $0.25 and the highest is $0.25

What is ARAV stock prediction ?

What is Aravive, Inc. stock quote today ?

Aravive, Inc. stock price is $0.0401 today.

Is Aravive, Inc. stock public?

Yes, Aravive, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap